Compare BioNano Genomics Inc (BNGO) vs Five9 Inc (FIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Five9 Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.77M), while Five9 Inc trades at $33.65 (market cap $2.33B). The key difference: Five9 Inc is far larger — about 169.2× BioNano Genomics Inc's market cap, and Five9 Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | FIVN | |
|---|---|---|
Market Cap | $13.77M | $2.33B |
Sector | Health | Technology |
52-Week High | $4.92 | $34.48 |
52-Week Low | $1.06 | $13.61 |
Enterprise Value | $16.38M | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.18, down 0.84% today, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company shows improving financial trends, with net losses narrowing significantly from -$232M in 2023 to -$26M in 2025, and recent earnings beats. Revenue remains steady around $29M, while analyst sentiment is positive with 57% buy ratings.
Outlook: BNGO presents a speculative opportunity with strong analyst support and improving fundamentals, but risks include persistent negative cash flows, high operating costs, and competitive pressures in genomics. The stock's low valuation multiples may attract value investors, yet profitability remains a key hurdle.
FIVN trades at $33.80, up 3.59% today, near its 52-week high of $34.58. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for three consecutive quarters. Revenue growth is accelerating, with 2025 revenue reaching $1.15 billion and net income turning positive at $39.42 million, marking a significant improvement from prior losses. Recent management appointments and AI-driven subscription growth are positive catalysts.
The outlook is positive given earnings momentum and analyst support, but risks include high valuation multiples, ongoing legal scrutiny, and dependence on competitive AI adoption. With 61% of analysts rating it a Buy and a consensus target of $32.67, near-term upside appears limited, but execution on guidance could drive further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
